Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC

Elvina Almuradova, Associate Professor of Oncology at Medicana Sağlık Grubu, shared a post on LinkedIn:

“The FDA has expressed concern that in patients with metastatic or unresectable esophageal squamous cell carcinoma, using immune checkpoint inhibitors as a first-line treatment may pose a risk of toxicity without offering a clear benefit for those with low PD-L1 expression (PD-L1 <1).”

Read further.
Source: Elvina Almuradova/LinkedIn